Literature DB >> 11758972

Regulation of gadd153 mRNA expression by hypoxia in pulmonary artery smooth muscle cells.

R Chen1, K S Harrod, J W Olson, M N Gillespie.   

Abstract

Hypoxia causes pulmonary hypertension and induces oxygen radicals in pulmonary artery smooth muscle cells (PASMCs). Since oxidative stress regulates gaddl53 expression, we examined gaddl53 mRNA in PASMCs cultured in a hypoxic environment. Gadd153 mRNA content was increased in PASMCs cultured for 24 hours in 1% oxygen. This increase was not abrogated by inhibition of protein synthesis. To explore the signaling pathways mediating hypoxic regulation of gaddl53 mRNA, the impact of calcium channel blockade by verapamil, G protein inhibition by pertussis toxin, and protein kinase C (PKC) down-regulation, was examined. Although none of these interventions reduced basal expression of gaddl53 mRNA in PASMCs, all of them suppressed the induction by hypoxia. In contrast, antioxidants had no effect. These observations indicate hypoxia induces gaddl53 expression in PASMCs through common signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11758972

Source DB:  PubMed          Journal:  Res Commun Mol Pathol Pharmacol        ISSN: 1078-0297


  3 in total

Review 1.  Hypoxia-responsive transcription factors.

Authors:  Eoin P Cummins; Cormac T Taylor
Journal:  Pflugers Arch       Date:  2005-07-09       Impact factor: 3.657

2.  Involvement of GADD153 and cardiac ankyrin repeat protein in cardiac ischemia-reperfusion injury.

Authors:  Mi Jin Lee; Yong Keun Kwak; Kyung Ran You; Byung Ho Lee; Dae Ghon Kim
Journal:  Exp Mol Med       Date:  2009-04-30       Impact factor: 8.718

3.  Abnormal chondrocyte apoptosis in the cartilage growth plate is influenced by genetic background and deletion of CHOP in a targeted mouse model of pseudoachondroplasia.

Authors:  Katarzyna A Piróg; Andreja Irman; Siobhan Young; Poonam Halai; Peter A Bell; Raymond P Boot-Handford; Michael D Briggs
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.